Edition:
India

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

84.78USD
16 Aug 2019
Change (% chg)

$0.84 (+1.00%)
Prev Close
$83.94
Open
$84.77
Day's High
$85.08
Day's Low
$84.27
Volume
1,618,713
Avg. Vol
1,480,788
52-wk High
$88.76
52-wk Low
$63.60

About

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded... (more)

Overall

Beta: 1.11
Market Cap(Mil.): $156,218.30
Shares Outstanding(Mil.): 1,764.18
Dividend: 0.32
Yield (%): 1.45

Financials

Abbott hits record high as diabetes device fuels profit beat

Abbott Laboratories beat analysts' estimates for quarterly profit and lifted its full-year earnings forecast on Wednesday, boosted by a near 64% jump in sales of its blood sugar monitoring device.

17 Jul 2019

US STOCKS-Wall St flat as railroads slide after CSX signals trade impact

* Dow flat, S&P off 0.05%, Nasdaq 0.06% higher (Updates to open)

17 Jul 2019

UPDATE 2-Diabetes devices power Abbott's profit beat, forecast raise

July 17 Abbott Laboratories beat analysts' estimates for quarterly profit and lifted its full-year adjusted earnings forecast on Wednesday, as the company benefits from strong demand for its blood sugar monitoring devices.

17 Jul 2019

Abbott to hike production of lower-cost glucose monitors as diabetes soars

CHICAGO Abbott Laboratories plans to ramp up manufacturing capacity for its lower-cost continuous glucose monitor, the FreeStyle Libre, by three to five times in the next few years, aiming to reach millions more patients worldwide, the company told Reuters.

16 Jul 2019

Abbott to hike production of lower-cost glucose monitors as diabetes soars

CHICAGO Abbott Laboratories plans to ramp up manufacturing capacity for its lower-cost continuous glucose monitor, the FreeStyle Libre, by three to five times in the next few years, aiming to reach millions more patients worldwide, the company told Reuters.

16 Jul 2019

FOCUS- Abbott to hike production of lower-cost glucose monitors as diabetes soars

CHICAGO, July 16 Abbott Laboratories plans to ramp up manufacturing capacity for its lower-cost continuous glucose monitor, the FreeStyle Libre, by three to five times in the next few years, aiming to reach millions more patients worldwide, the company told Reuters.

16 Jul 2019

Abbott device helps in cutting blood sugar in type 2 diabetics: study

Insulin-dependent patients with type 2 diabetes saw a significant drop in their blood sugar levels after wearing Abbott Laboratories Inc's continuous glucose monitoring system for three months compared with when they were not using the device, researchers said on Saturday.

11 Jun 2019

CORRECTED-Abbott device helps in cutting blood sugar in type 2 diabetics - study (June 8)

June 8 Insulin-dependent patients with type 2 diabetes saw a significant drop in their blood sugar levels after wearing Abbott Laboratories Inc's continuous glucose monitoring system for three months compared with when they were not using the device, researchers said on Saturday.

11 Jun 2019

UPDATE 2-Abbott Labs quarterly beat overshadowed by unchanged forecast

April 17 Abbott Laboratories Inc reported higher-than-expected quarterly profit and sales on surging demand for its glucose monitoring device, but an unchanged forecast along with regulatory uncertainty kept investors on the edge.

17 Apr 2019

Abbott Labs beats first-quarter expectations on higher diabetes devices sales

Abbott Laboratories Inc reported higher-than-expected first-quarter profit and sales on Wednesday on surging sales of its Freestyle Libre glucose monitoring device and as more of its heart devices were used in surgical procedures.

17 Apr 2019
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates